Adult T cell leukemia/lymphoma (ATLL) is one of the peripheral T cell malignant neoplasms strongly associated with human T cell leukemia virus type-I (HTLV-I). Although the viral transactivating protein Tax 
Introduction
Adult T cell leukemia/lymphoma (ATLL) is an aggressive, fatal malignancy of mature CD4 + T lymphocytes. [1] [2] [3] [4] The retrovirus, human T cell lymphotropic virus type I (HTLV-I), has been recognized as the etiologic agent of ATLL. [5] [6] [7] [8] HTLV-I is endemic in Southern Japan and the Caribbean basin. Thus, In the relatively indolent smoldering and chronic forms, the median survival is 2 years or more. In the acute and lymphomatous forms, the median survival time is about 13 months. 16 Because hematopoietic stem cell transplantation combined with chemotherapy has been applied for acute/lymphomatous ATLL, the survival rate will be progressed. Transformation from chronic to acute type occurs frequently. Acute and lymphomatous ATLL is characterized by high white blood cell counts with convoluted nuclei, hepatosplenomegaly, lymphadenopathy, skin lesions, frequent hypercalcemia, and a rapidly progressive terminal course. 1, [17] [18] [19] HTLV-I is also associated with chronic inflammatory disorders such as tropical spastic paraparesis (TSP/HAM)/HTLV-I-associated myelopathy, HTLV-I-associated arthropathy, alveolitis, dermatitis and uveitis. [20] [21] [22] [23] [24] [25] HTLV-I contains no typical oncogenes. [26] [27] [28] [29] The viral factor of HTLV-I responsible for induction of leukemia is proposed to be Tax, a regulatory protein encoded by the pX sequence of the virus, 30 which immortalizes human T cells and induces tumors in transgenic mice. [31] [32] [33] Tax transcriptionally activates the expression of certain cellular genes, including interleukin-2 (IL-2), IL-2 receptor (IL-2R), IL-8, 34 IL-10, 35 granulocytemacrophage colony-stimulating factor (GM-CSF), and several proto-oncogenes. On the contrary, Tax downregulates the DNA repair enzyme ␤-polymerase. 36 However, the role of Tax in leukemogenesis has not been precisely defined because of the following observations. The HTLV-I virus integrates randomly into the genomic DNA; the sites of insertion show that the transformation process can not be explained solely by the activation of proto-oncogenes by insertional mutagenesis or disruption of tumor suppressor genes. 37, 38 Transcripts of tax have been detected in the peripheral blood mononuclear cells (PBMNCs) in about 20% of asymptomatic carriers by nested RT-PCR, 1, 39 whereas ATLL cells usually do not express viral proteins including Tax. 40 These findings indicate that HTLV-I may be merely one of the factors in leukemogenesis of ATLL. Evidence that additional cellular events are required for the development of the malignant phenotype includes: (1) a long period of clinical latency (mean 55 years) precedes the development of ATLL; 41 (2) only a small percentage of HTLV-I infected individuals develop this malignancy (one patient/1000-2000 carriers/year); 41, 42 ( 3) leukemic cells of ATLL are monoclonal; 5, 43 and (4) a statistical analysis revealed that five independent genetic events were probably required to develop ATLL after viral infection of the target T cells. 44 Few details are known concerning the genetic events leading to acute/lymphomatous from chronic/smoldering ATLL. As we will show, the weight of evidence suggests that alterations of tumor suppressor genes lead to the progression to ATLL. An A family of serine/threonine kinases known as cyclindependent kinases (CDKs) regulates cell cycle progression in eukaryocytes. [46] [47] [48] [49] [50] Mammalian cells contain at least seven CDKs (CDK1- 7) 49,51,52 whose protein levels are constant throughout the cell cycle. The CDKs are either activated or inactivated at specific time points during the cell cycle. 48 Activation of CDKs requires their association with the regulatory subunits called cyclins. Twelve cyclins (A, A1, B1, B2, C, D1, D2, D3, E, F, G and H) 52, 53 have been described, which are expressed in a cell cycle-dependent manner. Among them, Dtype cyclins (D1, D2 and D3) and cyclin E are involved in regulating progression through G1 and entry into S phase, and therefore are termed G1 cyclins. [54] [55] [56] [57] The half-life of these cyclins is short (approximately 30 min). Ectopic expression of cyclin D1 accelerates the entry into S phase. 58, 59 D-type cyclins are associated mainly with either CDK4 or CDK6. 54, 57, 60 Cyclin E binds to CDK2. 61 Once cells enter S phase, cyclin E is degraded, and CDK2 forms complexes with cyclin A. This complex functions at least during the S phase. 62 The major substrate for the cyclin D-CDK complex is the retinoblastoma protein (pRb), a key tumor suppressor protein. 63, 64 During G0 and early G1, the Rb protein binds and inactivates a key family of transcription factors known as E2F. 65 At mid to late G1, Rb becomes extensively phosphorylated by CDK4/CDK6 which causes release of the E2F family of proteins from Rb. The E2F proteins play an important role in transactivating genes associated with DNA synthesis and cell division such as dihydrofolate reductase, thymidine kinase and c-myc. Thus, phosphorylation of pRb reverses its growth suppressive function and enables the activation of genes coding transcription factors that are key to the S phase of the cell cycle. 65, 66 Several oncoproteins of DNA tumor viruses, including E1A of adenovirus, E7 of papilloma virus, and large T of SV-40 virus, bind directly to and inactivate the tumor suppressor pRb to drive quiescent cells into a replicative state which may lead to cellular immortalization. 65, 67, 68 The overexpression of cyclin D is found in some types of lymphoma/leukemia cases and is the sine quo non of mantle cell lymphoma. Akagi et al 69 reported that cyclin D2 was expressed at a high level in HTLV-I infected T cell lines and was not expressed in T cell lines not infected with the virus. By contrast, HTLV-I infected T cell lines expressed CDK4 and CDK6 at lower levels. 69 However, whether HTLV-I uniformly enhances cyclin D and suppresses CDKs is unclear because in another study, expression levels of cyclin D1, D2 and D3 and CDK4 were not altered in T cells by Tax or HTLV-I infection.
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Cyclin-dependent kinases (CDKIs) and tumorigenesis
Cell cycle progression in eukaryotic cells is regulated by sequential activation and inactivation of CDKs. 55 The activities of CDKs are positively regulated by cyclins and negatively regulated by cyclin-dependent kinase inhibitors (CDKI) at different stages of the cell cycle. 50 Because all of the CDKIs block entry into S phase and thus inhibit initiation of DNA synthesis and proliferation, each are candidate tumor suppressor genes.
The CDKIs can be classified into two groups based on their structure. p15  INK4B ,  71 p16   INK4A   ,  72 p18  INK4C ,  73,74 and the more  recently described p19   INK4D , 74, 75 which have ankyrin repeat motifs, belong to one group of CDKIs known as the INK4 family. p16 is the first described gene in the INK4 family and is also known as MTS1 and CDKN2. The official HUGO nomenclature is CDKN2; however, the acronym p16 is much more widely used. The CDKIs of the INK4 family bind to CDK4 and CDK6 and inhibit their kinase activities, thereby resulting in arrest of the cell cycle. [72] [73] [74] [75] Mutations of p16 outside of the ankyrin repeats usually do not affect the function of the p16 protein in vitro. 76 Therefore, the ankyrin repeats are probably involved in the binding of INK4 family of proteins to CDK4 and CDK6. Expression of p16 was able to suppress the transformed phenotype of cells induced by H-Ras and CMyc, 77 and to produce G1 arrest in cell lines which retain functional pRb. 73, [78] [79] [80] [81] The p16 shares a great deal of nucleotide sequence homology with p15, which was identified as an inhibitor induced by transforming growth factor-␤ (TGF-␤). 71 The p15 gene is localized 25 kb upstream of the p16 locus on chromosome 9p21. 82, 83 This entire region is associated with chromosomal rearrangements and loss in many tumors. [84] [85] [86] [87] [88] [89] The p15 and p16 CDKI genes are very frequently altered, such as deletion and mutation, in a variety of tumors including hematologic malignancies. [90] [91] [92] [93] These aberrations are considered to contribute greatly to the abnormal growth properties of these tumor cells. 45, 85, [94] [95] [96] [97] Thus, both p15 and p16 are suggested as acting as tumor suppressors whose inactivation contributes to the development of human tumors.
The biochemical and biological properties of p18 and p19 suggest that they could have tumor suppressor functions similar to the p15 and p16 genes. [73] [74] [75] The genes for p18 and p19 are located at 1p32 and 19p13, respectively. 73, 75 Although chromosome 1p32 is frequently rearranged in a variety of solid tumors, almost no tumors with alterations of the p18 gene have so far been identified, with the rare exception of several cases of multiple myeloma and childhood T lineage acute lymphoblastic leukemia (ALL). 92, [98] [99] [100] [101] No rearrangements or deletions of the p19 gene were observed in hematologic malignancies including pediatric ALL with translocations involving chromosome 19p13. [102] [103] [104] Another group of CDKIs includes p21
Waf1 (also termed CIP1, SDI1 or CAP20), [105] [106] [107] [108] which contain a homologous amino-terminal CDK inhibitory domain. The p21 family inhibits the activities of several cyclin/CDK complexes including cyclin D/CDK4, cyclin E/CDK2, and cyclin A/CDK2. p21 also inhibits the activity of the proliferating cell nuclear antigen (PCNA), a DNA replication factor. 113, 114 The inhibitory activities for the CDK family proteins and for PCNA reside in separate protein domains of p21. 115, 116 At least two pathways for the induction of p21 have been described: a p53-dependent pathway activated by DNA damage and a p53-independent pathway activated by mitogens at the entry into the cell cycle. 105, 106, [117] [118] [119] The p27 is involved in blocking progression through the G1 phase in cells exposed to cyclic AMP 120 and TGF-␤. 121 Although the p21 family of proteins was originally thought to be exclusively an inhibitor of the cyclin/CDK, more recently it has been proposed as also acting as an assembly factor for the cyclin The same samples were analyzed for DNA and protein alterations of p53. Among the samples overexpressing p53 protein by immunohistochemical staining, one had a detectable p53 mutation. d The same samples were analyzed for DNA and protein alterations of p53. Immunohistochemical staining was performed for the samples with p53 mutation and revealed high expression in two and lack of expression in one. The same samples were analyzed for DNA, RNA and protein of p53. Among five samples, one sample had both mutation and overexpression of p53. f One has p53 mutation. All the samples #1 are included in the samples #2. D/CDK4 complex. 122, 123 Structural abnormalities of the coding region of p21, p27 and p57 genes are very rare in human cancers. [124] [125] [126] [127] The p53 gene is a nuclear phosphoprotein which induces transcription of p21 105 and the DNA repair gene, GADD45 128, 129 in response to DNA damage. Careful analysis of the p53 gene has shown that it is frequently mutated in more than 50 varieties of human tumors including lung, breast, thyroid, gastrointestinal, ovarian and brain tumors as well as lymphomas/leukemias. [130] [131] [132] [133] [134] [135] These observations support the concept that p53 functions as a tumor suppressor gene.
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Role of INK4 family in ATLL
The homozygous deletion of p16 gene has been detected at a very high rate in many types of tumor cells including leukemias, 83, 96, 98, 101, 137, 138 especially in T-ALL, in which it is deleted in about 70% of cases. 92, [139] [140] [141] [142] [143] [144] [145] Several investigators including ourselves have reported alterations of the p16 occurring in 17-68% of the acute and 5-26% of the chronic ATLL samples and the p15 gene was structurally abnormal in 21-30% of the acute and 0-13% of the chronic ATLL specimens. 90, [146] [147] [148] [149] [150] In total, genomic alterations of the p16 gene occurred in 55 of 136 acute/ lymphomatous (40%) cases and nine of 79 (11%) chronic/smoldering ATLL samples. For the p15 gene, 30 of 111 (27%) acute/lymphomatous cases and three of 60 (5%) chronic/smoldering ATLL samples had alterations. Both genes were often simultaneously deleted, which is consistent with the proximity of the two genes on chromosome 9p21, being separated by only 25 kb.
Point mutations of the p16 gene are exceedingly rare. They have occasionally been reported in B cell-type non-Hodgkin's lymphoma (NHL), 151 ALL 141,144,145 and chronic lymphocytic leukemia (CLL). 142, 143 Missense mutations (codons 43 and 97) and a nonsense mutation (codon 72) of p16 were identified in two acute and one lymphomatous ATLL, respectively. 149 Thus, the p16 gene is rarely inactivated by point mutations, but lymphoid malignancies may be more frequent target when it occurs. All of the mutations involved the ankyrin repeats. These data and a mutational analysis done by us show 76 that the ankyrin repeats are critical to the function of the protein.
The association of p15 and p16 deletions with the development of acute/lymphomatous but not chronic/smoldering ATLL suggests that these genetic events may help drive the late stage of leukemogenesis in ATLL. In our study, an instructive case had no detectable deletion of the p15 and p16 genes during the chronic phase whereas both genes were homozygously deleted in the acute phase. A chronic ATLL patient with homozygous deletion of the p16 gene progressed to acute ATLL and died within 6 months, indicating that loss of p16 can precede the transformation from chronic to acute ATLL. 90 Similarly, alteration of the p16 gene is involved in the progression to lymphoid blastic crisis from the chronic phase of chronic myelogenous leukemia (CML), 152, 153 as well as the evolution from low grade to high grade NHL. 91, 154 Furthermore, this is in agreement with the higher frequency of deletions of the p15 and p16 genes in high grade lymphoid malignancies, such as ALL, lymphoblastic or diffuse large cell lymphoma as compared to their low grade counterparts. 155, 156 Therefore, the development of deletions of the p15 and p16 genes help define a distinct clinical and pathological subgroup of hematologic neoplasms characterized as lymphoid origin, a pathologically high grade malignant behavior, progressive disease, and poor outcome. ATLL patients with deleted p15 and/or p16 genes have a significantly shorter survival than those with both genes preserved. None of the acute ATLL individuals who had either their p15 or p16 genes deleted, survived for 3 years, whereas those whose ATLL cells had these genes intact, survived up to 8 years. 146 Methylation of the 5′ CpG island of p15 and p16 genes is associated with transcriptional silencing of these genes in many neoplasms including leukemias and lymphomas. [157] [158] [159] [160] [161] [162] [163] [164] The p16 gene is more frequently methylated in fresh tumor cells isolated from patients with acute (47%) and lymphomatous (73%) than in those with chronic (17%) and smoldering (17%) ATLL. The expression of p16 mRNA was markedly decreased in the samples with methylated p16 gene, especially if the promoter region was methylated. In contrast, methylation of p16 was not identified in assymptomatic carrier or uninfected individuals. 165 Tax-immortalized T cell lines and normal CD4 + T cells expressed comparable levels of p16 mRNA. 69 The methylation of the p15 gene in primary ATLL cells has not been reported in any types of ATLL. These data indicate that alterations of p16 may be more relevant to the progression of ATLL than those of p15.
We have shown that structural changes of the p18 gene rarely occur in over 100 samples of ATLL and NHL including primary samples and cell lines. PCR-SSCP analysis revealed an occasional polymorphism at codon 114 (GGC to GGT) which has been reported in other tumors. 166 Expression of p18 was often undetectable in HTLV-I-associated cell lines whereas it was expressed in normal CD4 + T cells, HTLV-I noninfected leukemia/lymphoma cell lines, and purified leukemic cells from HTLV-I uninfected acute leukemia patients. 69, [167] [168] [169] These results suggest that inactivation of p18 may be peculiar to ATLL. Further studies of expression of p18 in fresh ATLL cells will also be of interest.
Abnormalities of the p19 gene are apparently rare events in hematologic malignancies. Structural alterations of p19 were not detected in 45 primary ATLL samples (acute/ lymphomatous and chronic) and two ATLL cell lines (SO-4 and ST-1) using Southern blot analysis and PCR-SSCP. 103 Expression of p19 mRNA was detected in both HTLV-I infected and non-infected T cell lines, but levels appeared to be slightly decreased in the HTLV-I infected T cell lines. 69, 168 Protein amounts of p18 and p19 in primary ATLL samples have not yet been reported.
Oncogenic effects of Tax may be due to its interaction with cellular proteins, consisting of several transcription factors including CREB, NF-B and SRF, [170] [171] [172] [173] and the family of IB transcriptional inhibitors. 174 IB family proteins contain 6-8 ankyrin motifs. 175 Tax binds to the ankyrin motifs of IB and inhibits the formation of the IB-NF-B complex, causing nuclear translocation of active NF-B. 174, 176 In a similar way, Tax binds to the four tandem repeats of the ankyrin motif in the p15 and p16 proteins and counteracts their inhibitory Leukemia activity, resulting in activation of CDK. 70, 168 Consistent with these observations, HTLV-I infected T cell clones and forced Tax-expressing cells developed resistance to p15-mediated growth arrest induced by TGF-␤. 168 This phenomenon correlated with the inability of TGF-␤ to prevent hyperphosphorylation of pRb. 177 Also, Tax suppressed p16-mediated inhibition of U2OS cell growth. 70 The p15 and p16 can bind to Tax, but p18 and p19 cannot, 168 probably because the ankyrin motifs are only loosely conserved in the latter two CDKIs. Similarly, Tax preferentially binds to NF-B-2 p100 as compared to NF-B-1 p105, 178 both of which have ankyrin motifs, suggesting Tax has some selectivity in its binding of ankyrin motifs.
Interestingly, a point mutation of p16 occurs in the HTLV-I infected MT-1 cells, and these cells do not express Tax. In contrast, wild-type p16 is abundantly expressed in MT-2 and HUT102 cells and they do express Tax. These results suggest that inactivation of p16 either by genetic alteration or possibly Tax expression is important for T cell immortalization.
The p18 gene is transcriptionally repressed by Tax through the E-box element between −710 and −510 of the p18 promoter. 168 This observation is consistent with recent reports on Tax-mediated trans-repression through the E-box element of the DNA polymerase ␤, lck and bax genes. 36, [179] [180] [181] However, p18 mRNA is detected in several tax expressing cell lines: ATL-1K (HTLV-I infected cell line) and the stably tax transfected Jurkat cell lines. 167 In addition, decrease of p18 mRNA expression is more obvious in HTLV-I infected than in Taximmortalized T cells, 69 so Tax may not be the only determinant decreasing the expression of p18. Furthermore, while Tax repression may be important for the early carrier phase, it is probably not very relevant for the later phase of the disease when most of the HTLV-I infected cells no longer express Tax.
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Role of p21 family in ATLL
The first identified CDKI was p21, 71, 72, 74, 182 which is a protein accumulating in both senescent human fibroblasts and a melanoma cell line during its differentiation. 74 In nontransformed cells with a diploid karyotype, the p21 is an abundant protein component that forms a quaternary complex with most of the cyclin/CDK complexes (cyclin A/CDK2, cyclin B/cdc2, cyclin E/CDK2 and cyclin D/CDK4) and PCNA. 79, 80 Transfection with a p21 cDNA in tumor cell lines resulted in suppression of their growth in vitro. 71 Additional studies showed that over-expression of p21 inhibited proliferation of transformed cells in vitro as well as in vivo. 183, 184 A relationship between expression of p21 and apoptosis in a p53-independent manner was reported in HTLV-I-transformed lymphocytes after their exposure to adriamycin. 185 These observations suggested that p21 could be a tumor suppressor. However, mutations within the coding region of the p21 gene have almost never been detected in any type of malignancy including ATLL. 90, [186] [187] [188] The p21 mRNA was expressed more abundantly in both IL-2-dependent and -independent HTLV-I infected T cell lines compared with normal T cells. 69 This phenomenon was observed irrespective of the functional status of p53. 189 At the protein level, the expression of the p21 was also elevated in HTLV-I infected T cell lines. 189 In contrast, p21 expression was almost undetectable in uninfected human T cell lines known to have mutated p53 genes (HUT78, Jurkat and CEM). 69, 189 The following observations support the hypothesis that Tax may be responsible for the high expression of p21.
Leukemia First, T cell lines immortalized by tax express p21 mRNA at much higher levels than normal CD4 + T cells. 69, 189 Secondly, p21 expression is induced in Jurkat cells transfected with tax; 189 and thirdly, in related studies, transient transfection of tax was able to activate a reporter gene attached to the p21 promoter even in p53 null cells.
189 Surprisingly, however, deletion of the p53 response element in the p21 promoter correlated with a loss of Tax inducibility as measured by reporter gene study. 189 These findings suggest that the Tax protein is at least partially responsible for the p53-independent expression of p21 in HTLV-I infected cells; however, the p53 response element or a sequence in the vicinity of this site in the p21 promoter region is required for Tax transactivation.
The constitutive high level expression of p21 in HTLV-I infected T cell lines is paradoxical because these cells proliferate rapidly despite the presence of high levels of this protein.
Other examples of this dysregulation are the high expression level of p21 in brain tumors 190 and acute myelogenous leukemia (AML) cells, 191 but not in normal brain and bone marrow cells. Mutational inactivation of p21 has been shown not to be the case. 124, 188 In HTLV-I infected T cell lines, the antiproliferative effect of p21 might be directly suppressed or alternative pathways might stimulate cell cycle progression regardless of the presence of a functional p21. Tax, like Sv40 T-antigen, 72 c-Myc, 192 or B-Myb, 193 might be able to cancel the anti-proliferative function of p21. Also, the elevated amounts of p21 produced in HTLV-I infected cell lines might still be under the level required to promote G1 arrest; recent data indicate the existence of a dose-dependent effect of p21 to inhibit cyclin-CDK complexes. 88 Alternatively, the cells could have an alteration in downstream target of p21. This has been reported in melanoma which develop a mutation of CDK4. 194, 195 In addition to being a potent inhibitor of most cyclin/CDK complexes, 45, 72, 182, 196, 197 p21 also promotes the assembly of cyclin D/CDK4 complex. 88, 89 The high expression of p21 induced by Tax in HTLV-I infected T cells might, therefore, play a role in the proliferation of these transformed cells by acting as a factor that continuously promotes the assembly and activation of cyclin/CDK complexes. Furthermore, recent studies have raised the possibility that the p21 may function as a transcriptional coactivator for NF-B. 198 Elevated NF-B binding activity has been suggested to contribute to the oncogenic properties of Tax, possibly by disrupting the normal growth regulatory mechanisms of cellular genes. 199 Although in vitro, high levels of p21 protein occur in HTLV-I infected T cells and Tax immortalized T cell lines, most ATLL cells in vivo do not express p21 protein. In our study, only 3% of lymphomatous ATLL cells expressed p21 protein whereas 26% of the cells in other high grade lymphomas including Burkitt and lymphoblastic lymphomas expressed p21 protein by immunohistochemical staining (unpublished data, manuscript in preparation). Furthermore, Mansukhani et al 200 also revealed that only one of four ATLL cases showed p21 immunoreactivity in more than 10% of tumor cell nuclei. Levels of p21 protein are low in primary ATLL cells probably because Tax is not expressed in these cells. Another possible explanation is that p21 may be rapidly degraded as reported for p27 protein in colorectal carcinomas; the latter protein is degraded by increased proteosome activity in the tumor cells. 201 We found only two cases of p27 alterations among 42 ATLL samples using Southern blot and PCR-SSCP analyses; a homozygous deletion and a point mutation. 202 Thus, development of ATLL is usually not the result of a structural alteration of p27. The p27 mRNA was detected in both HTLV-I infected and non-infected T cell lines, however, the level was slightly higher in HTLV-I non-infected T cell lines. 69 To date, the protein level of p27 in ATLL has not been reported.
The p57 is transcriptionally repressed in Wilms' tumor 203 and CML during blast crisis 126 but mutations of the p57 gene have not been detected in any neoplasm. 126, 127 A causative role of p57 in the development of ATLL is not clear at this time.
Role of p53 in ATLL
p53 is a well characterized tumor suppressor gene on chromosome 17p. It is implicated in cell cycle regulation through induction of p21. While p53 is also known to have a role in apoptosis, 204, 205 the mechanisms by which p53 induces apoptosis are still largely unknown. Inactivation of the p53 gene contributes not only to dysregulation of the cell cycle machinery, but also to defects in the DNA repair system and to cellular immortalization. 206 The p53 gene is frequently mutated in a variety of tumors including hematologic malignancies. 132, 133, 207, 208 Unlike functional p53, which is rapidly degraded within 5 to 20 min after its synthesis, 209 mutant versions of the proteins have a half-life of 4 to 8 h 210 and accumulate in the cells, thus becoming immunohistochemically detectable.
At most, 50% of individuals have p53 mutations in primary ATLL cells. 30, [211] [212] [213] [214] In our series, leukemic cells of five of 10 acute/lymphomatous ATLL cases had homozygous p53 mutations. One informative case had no detectable p53 mutation in the ATLL cells during the chronic phase of the disease, but had a homozygous point mutation when he progressed to acute ATLL. 212 Our results were mirrored in those of other investigators; 211, 213 and taken together, eight of 28 (29%) acute/lymphomatous and none of 11 (0%) chronic/smoldering ATLL samples were found to have mutations of p53. These data suggest that inactivation of the p53 gene is frequent and associated with the transition to a more aggressive leukemic phenotype. Similarly, in other lymphomas, p53 mutations also occur as relatively late events in tumorigeneis. 215, 216 In cell lines, mutations of the p53 gene can be found only in a minority of HTLV-I-transformed cell lines.
We have previously shown that the several CCGG tetranucleotides throughout the coding region of the p53 gene are fully methylated in HTLV-I-transformed cells. 217 Endogenous methylation of cytosines and transition of these methylated cytosines to thymidines by deamination is considered as one of the mechanisms of p53 mutations. 218 Repression of DNA polymerase ␤, a DNA-repair enzyme, in HTLV-I-immortalized cells 36 may also cause genetic alterations including mutations of the p53 gene in ATLL.
The transcription level of p53 in ATLL was higher than that of normal PBMNC regardless of the mutational status of p53. 213 For cell lines, expression of p53 mRNA by Northern blot hybridization in MT-1 and ATL-1K (both with a p53 mutation) and MT-2 (wild-type p53) cell lines was also high compared with that of normal PBMNC. 213 The protein level of p53 in primary ATLL samples is not conclusive from the data available. Several investigators reported that the samples with high expression of p53 protein had missense mutations. 211, 214 This contrasts with the finding that some ATLL cases with p53 mutations lack detectable p53 protein. 29, 200 Furthermore, several cases having wild-type p53 highly express this protein. 200 In cell lines, elevated steady-state levels of p53 protein were demonstrated in both HTLV-I-transformed cell lines having a wild-type sequence of the p53 coding region and those with a mutated version of the gene (MT-1 and HUT-102). 189, 214, 219, 220 Thus, wild-type as well as mutant p53 are stabilized post-translationally in HTLV-I infected T cell lines, probably due to prolongation of protein half-life. 219 We have found that the half-life of p53 was 2 h in HTLV-I-transformed cells, 217 which was about six times that of human wild-type p53. 221 Low expressors of p53 protein do not have mutations of the gene in HTLV-I infected cell lines. 214 In one study, Tax expression was found in ATLL samples expressing high levels of wild-type p53 protein, but it was not detectable in cells that either expressed low levels of p53 or had a mutation of the gene. The levels of p53 mRNA were similar among the samples regardless of p53 protein levels. 214 Post-translational mechanisms other than missense mutation would thus appear to stabilize p53 in the Tax-expressing cells but not in those containing undetectable levels of Tax. Alternatively, the co-expression of Tax and high levels of p53 may be epiphenomenon.
Some experimental evidence suggests that the function of wild-type p53 in HTLV-I-transformed cells appears to be impaired. Some data concern the lack of appropriate p53-mediated response to ionizing radiation. Hematopoietic cells with functional p53 undergo apoptosis after ionizing radiation; 222, 223 however, apoptosis was not induced in either E55/PL (p53 mutation+) or MJ (p53 mutation−) HTLV-I infected T cells. 189 These observations are consistent with other reports that p53-responsive elements are not appropriately upregulated in HTLV-I infected T cells, particularly in IL-2-independent cell lines. 220 In another study, luciferase assays with a reporter plasmid containing p53-binding sites revealed an impairment in the transactivating function of p53 in the Tax-expressing T cells, even though the cells had wild-type conformation of the p53 gene. 224 An additional suggestion of p53 dysfunction in HTLV-I infected cells was shown by a weak induction of GADD45 expression after ␥-irradiation. A functional p53 normally mediates a robust expression of GADD45 in response to DNA damage. 128, 129 For example, normal T cells responded to ␥-irradiation with a mark increase of expression of the GADD45 gene. In contrast, under the same conditions, minimal enhancement of GADD45 transcription was observed in HTLV-I-infected cell lines and a Tax-transformed cell line. 189 Functional impairment of p53 is associated with several DNA transforming viruses. Adenovirus, SV40, and human papillomavirus encode proteins that either bind and functionally inactivate p53 (E1B of adenovirus and T antigen of SV40), or degrade the p53 protein (E6 protein of papilloma virus). 225 The mechanism of p53 impairment in HTLV-I infected T cells could be due to interactions with a viral protein or a virally induced cellular protein. However, no complex formation between p53 and Tax has been observed, 214, 219, 220, 226 nor does Rex, another HTLV-I virus specific regulatory protein, complex with p53. 220 Moreover, Tax does not directly induce changes of p53, since early passage of Tax-transduced primary T cells does not show aberrant expression or function of p53; it is observed only in fully immortalized cells. Dysfunction of p53 is probably a rather late event in the Tax-induced immortalization process. 224 In fact, one series of experiments suggested that impaired p53 function was linked to progression from IL-2-dependent to IL-2-independent growth in HTLV-I-transformed lymphocytes. Levels of p53 protein were consistently higher in IL-2-indeLeukemia pendent HTLV-I-transformed cell lines compared with IL-2-dependent ones. Furthermore, reporter gene studies using a p53 response element suggested that a dysfunctional p53 was observed only in IL-2-independent cell lines. 220 A new member of the p53 gene family, p73, has been recently isolated. 227 Overexpression of p73 can induce expression of p21 and cause apoptosis in the p53-negative osteosarcoma cell line, SAOS-2. 228 Thus, p73 could be a new tumor suppressor. No structural alterations of p73 were identified in over 100 samples from leukemia and lymphoma cell lines and patient samples. Gene expression of p73 was not detectable in eight of 21 T-ALL/lymphoblastic lymphoma (LBL) cell lines and three of eight T-ALL/LBL patient samples. However, only one ATLL cell line, HUT-102, was studied and found to express p73. 229 The role of p73 in the development of ATLL is an important issue to be addressed by analyzing a large number of ATLL samples.
Role of Rb in ATLL
We looked for structural alterations of the entire Rb gene including the promoter region in 40 primary ATLL and two ATLL cell lines (SO-4 and ST-1) using Southern blot and PCR-SSCP analyses. Homozygous deletions of exon 1 were found in two primary cases for an incidence of 5% (one of 21 acute, none of four lymphomatous, and one of 15 chronic ATLL). 230 Hangaishi et al 148 also reported that structural alterations of the Rb gene were not found in 19 ATLL cases by Southern blot analysis. However, in the same series, five of 10 ATLL samples (50%) had either undetectable or remarkably low levels of expression of the Rb protein. 148 Hypermethylation of the promoter region of Rb has been associated with decreased expression of the Rb gene in retinoblastomas [231] [232] [233] and, thus, a similar phenomenon may occur in ATLL.
Several investigators have proposed that inactivation of the Rb locus may contribute to progression rather than to initiation of many solid tumors. 234, 235 However, less is known concerning hematologic malignancies. The frequency of either low or non-detectable expression of Rb in CLL does not change with either clinical progression or time from diagnosis, suggesting that loss of Rb expression is more closely associated with the development rather than the progression of CLL. 236, 237 In our study, because the frequency of Rb deletion was similar in acute ATLL (1/21) and chronic ATLL (1/15), loss of the Rb gene is probably not associated with progression of the disease. Future studies should measure the level of Rb protein in different stages of ATLL.
An inverse correlation occurs between functional integrity of p16 and Rb in many tumor cell lines and primary tumors; cells with a p16 deletion often have a wild-type pRb and vice versa. 106, 116, 118, [238] [239] [240] Moreover, forced over-expression of wild-type p16 induced G1 arrest in pRb-positive cells but had no effect in pRb-negative cells. 94, [99] [100] [101] [102] The case with p53 is less clear, with some studies showing [241] [242] [243] and other reports not finding 106, 148 an inverse correlation between a tumor having a p53 mutation and having normal p16 and Rb genes. The study of DNA-transforming viruses would lead to the prediction that the elimination of both p53 and Rb is more transforming than the inhibition of either one alone. The papilloma virus produces E6 (inactivates p53) and E7 (inhibits Rb); the adenovirus synthesizes E1A (inhibits Rb) and E1B (inactivates p53); and SV40 makes the large T antigen (inhibits both Rb and p53). Furthermore, mice deficient in both p53 and Rb showed a faster rate of tumor growth and a shorter survival rate than mice deficient in either the p53 or Rb gene. 244 Thus, a growth advantage may result from both being inactivated in the same cells.
Aberrations of CDKIs, Rb, and p53 in ATLL as examined by Hangaishi et al 148 and ourselves 90, 103, 167, 202, 230 are summarized in Table 3 . Because of the short distance between p15 and p16, both genes are often co-deleted and can be thought of as a group. Notably, the ATLL samples and cell lines had either a CDKI, Rb or p53 abnormality; however, except for one case, none of these samples had more than one alteration of these three families of cell cycle-related proteins. Taken together, the results emphasize that the CDKIs, Rb and p53 proteins are working on a common pathway of controlling the S phase of the cell cycle. Inactivation of one part of this pathway possibly alleviates the need for inactivation of other genes in the development of ATLL.
Role of DNA mismatch repair genes
Microsatellites are short tracts of (CA)n nucleotide repeats existing throughout the genome. Microsatellite instability (MSI) initially reported in hereditary nonpolyposis colorectal cancer (HNPCC) 245 represents either an expansion or reduction of these sequences. This phenomenon appears to reflect multiple replication errors 246 owing to germ line mutations of mismatch repair genes including human MutL homologue 1 (hMLH1), 247, 248 human MutS homologue 2 (hMSH2), 249, 250 human post-meiotic segregation 1 (hPMS1) and 2 (hPMS2), 251, 252 and GT-binding protein (GTBP). 253 Several studies have shown that mice engineered to be deficient in MLH1, MSH2 or PMS2 had MSI. [254] [255] [256] [257] MSI has been observed not only in solid tumors, but also in hematologic malignancies such as blastic crisis of CML, 258 AML, 259 aggressive lymphoma in HIV infected patients 260 and ALL. 261 We have shown that about 40% of ATLL samples had MSI as the individuals evolved into their acute/lymphomatous phase. 262 This frequency was higher than in other hematologic malignancies. One possibility is that MSI in ATLL is associated with the progression rather than the initiation of the disease, similar to what occurs in colon and gastric cancers [263] [264] [265] [266] [267] [268] and the blastic crisis of CML. 258 The predisposition to lymphoid tumors was reported in MLH1-, MSH2-and PMS2-deficient mice. 255, 256, 269 Development of lymphoid tumors such as ALL, CLL, and malignant lymphomas was also reported in human HNPCC kindreds. [270] [271] [272] [273] These observations imply that defects in the mismatch repair apparatus may cause accumulation of mutations in key oncogenes or tumor suppressor genes as well as in microsatellite sequences, thus contributing to the development of tumors. 250, 251, 274 However, the proportion and spectrum of sporadic cancers associated with mutations in mismatch repair genes has not been clearly elucidated at this time. Furthermore, the relationship between mutations of mismatch repair genes and MSI have not been observed clearly in sporadic tumors of various tissue with several exceptions. 266, [275] [276] [277] [278] [279] [280] We looked for genetic alterations of the hMSH2 gene in 41 ATLL samples and two ATLL cell lines using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique. Six ATLL samples showed two types of base changes of hMSH2, which probably represent polymorphisms. 280 Also, to date, mutations of the hMSH2 gene have not been detected in other hematologic malignancies. 281 Hangaishi et al 282 found the mutations of the hMLH1 gene in lymphoid leukemia cell lines only. However, a HTLV-I infected cell line, MT-1, was found to have a wild-type hMLH1 gene. 279 Germ line mutations in hMSH3 have not been found in a variety of neoplasms including ATLL. 279, 283, 284 Studies have not yet expanded to the expression and methylation status of mismatch repair genes in ATLL although lack of expression of hMLH1 owing to cytosine methylation of the hMLH1 promoter region has been observed in sporadic colon tumors as well as colon and endometrial tumor cell lines. 279 Somatic frameshift mutations of coding repeats within the TGF-␤RFII, Bax, IGFIIR, hMSH3, and E2F4 (one of E2F family) genes are recurrent targets of MSI in many kinds of cancers. We have identified frameshift mutations at a multiple trinucleotide AGC (serine) repeat within the coding exon of the E2F4 gene in two of 10 (20%) acute/lymphomatous ATLL samples having MSI, suggesting that mutations of the E2F4 gene, presumably caused by an abnormality of one of the DNA repair genes, may participate in the progression of ATLL. No mutations were found in the single nucleotide repeat sequences within the TGF-␤RFII, Bax, IGFIIR, and hMSH3 genes. 284 Besides the mismatch repair proteins, other genes of DNA replication and repair system should be considered as possible mutational targets including those coding for helicase (BLM, WRN, XH2), DNA polymerase, double-strand break repair protein (RAD family), and nucleotide excision repair protein (XP, PCNA). In fact, the activity of DNA polymerase is low in HTLV-I-immortalized cells.
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Other candidate tumor suppressor genes in ATLL From several studies, chromosome 6q appears to be involved in the pathogenesis of a number of solid tumors. [285] [286] [287] In hematologic malignancies, deletions involving the long arm of chromosome 6 are observed primarily in lymphoid malignancies, ie ALL, [288] [289] [290] lymphoproliferative disorders and NHL. 288, [291] [292] [293] [294] These results indicate that the long arm of chromosome 6 harbors a yet uncharacterized tumor suppressor gene(s) that is altered in many tumors. Cytogenetic studies showed that chromosome 6q is also often affected in acute/lymphomatous ATLL. 295, 296 We have identified a 4 cM commonly deleted region on chromosome 6q15-21 in samples of acute/lymphomatous ATLL by analysis for loss of heterozygosity. 297, 298 The evolution of chronic/smoldering to acute/lymphomatous ATLL may be fostered by inactivation of a putative tumor suppressor gene on the locus.
The DPC 4/SMAD 4 gene was identified as a candidate tumor suppressor gene at 18q21, with inactivation playing a possible role in the genesis of pancreatic cancers. 299 We examined the structural status of the DPC 4/SMAD 4 gene using Southern blot and PCR-SSCP analyses for 43 ATLL samples as well as several other types of tumors. None of the primary tumor samples had a detectable abnormality, indicating that alterations of the DPC 4/SMAD 4 gene, unlike pancreatic cancer, are not associated with the occurrence of ATLL. and assembly of cyclin/CDK complex. Tax transcriptionally represses p18 and functionally inactivates p15/p16 by binding them. Hyperexpression of IL-2 and IL-4 receptors induced by Tax in virally infected lymphocytes 301, 302 perhaps results in autocrine growth stimulation through production of IL-2 and other lymphokines. 27, 303 Tax can upreglate a number of cellular genes including proto-oncogenes (c-fos, c-jun and c-myc) and immediate-early genes (erg-1 and -2) in addition to growth factors. All of these Tax-related phenomena promote cell growth and cause a polyclonal or oligoclonal increase of the HTLV-I infected T lymphocytes. In vitro, HTLV-I infected T cells evolve from IL-2-dependent to IL-2-independent, suggesting that their growth is not maintained by an autocrine/paracrine mechanism. Functional inactivation of p53 protein might contribute to the abrogation of IL-2-dependent growth in HTLV-I infected T cells. Also, the Jak-STAT pathway may be activated constitutively in IL-2-independent HTLV-I-transformed T cells. 304 While a link between this pathway and that of p53 is not clear at present, they may both be important in the acquisition of IL-2 independence.
The polyclonal and then oligoclonal expanded population of the HTLV-I infected T cells may have a slight growth advantage over normal T cells. After these initial stages, expression of Tax disappears followed by disappearance of p21. Evolution from chronic to acute ATLL may result from additional inactivations of tumor suppressor genes such as p53, p15, p16, p21, and Rb. Also, a low p21 level itself enhances cell growth because p21 promotes the assembly of active cyclin/CDK complexes at low concentrations whereas p21 inhibits activity of the complexes at higher concentrations. 89 If our thesis is accurate, ATLL will provide a valuable model for analyzing the role of tumor suppressor genes and multiple genetic events in the clonal development of cancer.
Gene therapy and other therapeutic approaches for ATLL
The therapeutic restoration of expression of wild-type tumor suppressor genes in ATLL might eventually involve gene therapy. In several model systems, features of the tumor phenotype can be suppressed in vitro through the restoration of expression of a tumor suppressor gene such as p53 and Rb. Highly efficient and targeted gene delivery vectors must be developed to be clinically useful.
Immunotherapeutic approaches may also be possible. If the epitopes of mutant tumor suppressor genes were displayed on the malignant cells and could be presented to T lymphocytes by class I major histocompatibility complex molecules on the cell membrane, a cytotoxic immune response against these tumor cells might occur. 305 A murine model has shown that a cytotoxic immune response can occur against cells expressing mutant p53. 306 In addition, autoantibodies to p53 have been identified in some cancer patients although no evidence exists that these antibodies are directed against mutant p53 or that these individuals have an improved clinical response to their cancer. [305] [306] [307] Finally, novel chemotherapy and/or irradiation treatment schedules can be given to individuals with ATLL. DNAinjured cells with a p53 mutation do not stop at the G1 phase of the cell cycle for DNA repair before beginning DNA synthesis. This contrasts to cells with wild-type p53, which enforces a pause at the G1 phase of cell cycle after DNA damage. Therefore, the difference in the cell cycle control after DNA damage between malignant cells having an inactivated p53 and normal cells expressing wild-type p53 can be utilized to optimize chemotherapy and/or irradiation treatment.
Conclusion
Compelling evidence supports a pivotal role for altered tumor suppressor genes involved in leukemogenesis and lymphomagenesis of ATLL as well as progression of the disease from the chronic/smoldering to the acute/lymphomatous type. Disorder of cell cycle control exists in HTLV-I infected T cells during the transformation mediated by Tax. Further investigations are needed as to how the alteration of cell cycle regulatory genes are involved in the aberrant growth of HTLV-I infected T cells. Recent technical development of DNA microarray analysis will clarify the master gene(s)/molecule(s) for development and progression of ATLL. The mutant tumor suppressor genes may also provide a clue for innovative therapeutic approaches to treat ATLL.
